English
 

Wei Xu

Wei Xu
Partner

Mr. Wei Xu is a Partner at Decheng Capital and has been with the firm since 2017. He is currently serving on the boards of Accuragen, AnHeart Therapeutics and Mynosys.

At Decheng, Mr. Xu focuses on investments in biotechnology and medical technology companies in China and US. He currently serves on the boards of AccuraGen, Ketai Medical, and GeneMDx. He also serves as the board observer of MDCO Technology and Apexigen.

Prior to joining Decheng, Mr. Xu was director of Denlux Capital and served on the boards of Cirina (acquired by GRAIL), BEST (NYSE: BSTI), and SINOMED. His investment portfolio also includes Shengda (002259.SZ), SCYAHUA (002497.SZ), Dadifengyuan (acquired by Yonker, 300187.SZ), SZJECH (acquired by Orient Scape, 002310.SZ), NCM China (acquired by Tencent), Hsyuntai, Baoji Clinic, Immune-Onc., etc.

Mr. Xu received Master degree in Economics from University of Oslo, and a BS degree in College of Biomedical Engineering & Instrument Science from Zhejiang University.

 

Min Cui, Ph.D.
Managing Director
Victor E. Tong, Jr.
Partner
Nick Pliam, M.D., Ph.D.
Partner
Y. Katherine Xu, Ph.D.
Partner
Qiang Xu, Ph.D.
Partner
Wei Xu
Partner
Peter Colabuono
Principal
Tony Tong, Ph.D.
Principal

Claire Chin, M.D., MBA
Associate

Aaron Li, MBA
Associate
Yang Lu, MBA
Associate
Dan Zabrowski, Ph.D.
Venture Partner
Copyright © 2011 Decheng Capital LLC. All Rights Reserved.